The cartilage damage ACL and meniscus injuries often leave behind

Persistent aching or swelling in the knee after ACL reconstruction or meniscal surgery is not always a sign that something has gone wrong with the primary repair. For a significant proportion of patients, a focal cartilage lesion was present at the time of the original injury but was not the primary focus of treatment — and it is this unaddressed damage that continues to cause symptoms.

The co-occurrence is well documented. Slauterbeck et al. (JBJS Am, 2009) mapped the pattern of meniscal and cartilage lesions in patients sustaining ACL tears, establishing that concomitant chondral injury is a predictable finding rather than an incidental one. Cartilage injuries commonly accompany both ligament damage and meniscus tears at the time of the original trauma.

Meniscal loss creates a separate but overlapping risk. Partial meniscectomy is associated with measurable radiographic osteoarthritis progression over 5–12 years (Longo et al., J Knee Surg, 2019), while Pengas et al. (JBJS, 2012) followed patients for 40 years after adolescent total meniscectomy, demonstrating sustained long-term cartilage consequences. Because the meniscus distributes load across the joint surface, its removal accelerates wear on the underlying cartilage.

Cartilage itself offers little help once injured: it is avascular, and focal defects exceeding roughly 1 cm in diameter tend to enlarge over time rather than stabilise, moving toward post-traumatic osteoarthritis if left unaddressed.

The question for patients in this position is whether there is a treatment option suited to the post-injury window — before that progression becomes irreversible.

Why cartilage cannot repair itself — and why the timing of treatment matters

The body does attempt a response. When a focal chondral defect forms, a scar-like tissue called fibrocartilage — composed predominantly of Type I collagen rather than the Type II collagen of native hyaline cartilage — may partially fill the void. This repair is imperfect: fibrocartilage is mechanically softer, less resilient under cyclical loading, and tends to break down over time rather than consolidate into durable joint surface.

This is where the repair window concept becomes practically useful. In the months and years following a cartilage injury, the joint is in a state of focal loss rather than generalised degeneration. Treatments designed to support new matrix formation can work within the existing joint architecture. Once post-traumatic osteoarthritis is established more broadly, the clinical goal shifts from focal cartilage support to joint-level management — a different conversation with different options.

Meniscal loss, already noted as an accelerating factor, compounds this by increasing mechanical stress on the remaining cartilage surface and bringing that broader degeneration closer.

For patients still experiencing swelling or mechanical symptoms six months after ACL reconstruction or meniscal surgery, this does not mean the window has passed — it is often the signal that a cartilage assessment is overdue. What that assessment reveals — defect size, grade, the condition of the surrounding tissue — determines which treatment options are appropriately matched to the joint's current state.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller® is classified as a CE-marked Class III medical device — not a drug, not a cell therapy, and not a conventional filler. Understanding what it actually is helps explain both what it can do and what it cannot.

The active material is Type I collagen extracted from rat-tail tendon using a weak-acid, non-enzymatic process. That detail matters clinically: conventional pepsin-based extraction strips away the telopeptide regions at the ends of each collagen molecule — the sites that govern how collagen fibres cross-link with one another. By preserving those regions intact, meidrix biomedicals produces a scaffold that assembles itself more completely once inside the joint, behaving more like the body's own connective tissue matrix than a processed collagen alternative.

Delivery is via an outpatient, ultrasound-guided injection. The liquid collagen is placed directly over the cartilage defect; at body temperature it polymerises in situ, transitioning from a fluid to a stable hydrogel that fills and conforms to the defect space. No surgical incision is required.

The repair process that follows is best described as acellular matrix-induced chondrogenesis. The scaffold itself contains no transplanted cells — instead, it acts as a chemotactic signal, drawing the patient's own progenitor cells inward from the surrounding synovium and subchondral bone. Those recruited cells begin depositing a cartilage-like extracellular matrix within the scaffold architecture. This is not cartilage regrowth in any immediate sense; it is a process by which the body's repair mechanisms are given a structural platform to work within.

Maturation is gradual. MRI imaging in published series shows mean MOCART scores rising from approximately 65 at four weeks to over 81 at one year, confirming that tissue development continues progressively rather than plateauing early. Patients and clinicians should expect the meaningful phase of repair to unfold over six to twelve months.

Who is likely to benefit — patient and defect profile

Several factors point toward ChondroFiller injection as an appropriate next step — and understanding them helps frame what a specialist assessment will actually examine.

The clearest candidates are patients with focal Grade III or IV chondral lesions confirmed on MRI or identified during prior knee arthroscopy. These are discrete areas of cartilage loss rather than diffuse joint-wide degeneration — the kind of damage that frequently emerges as a concomitant finding alongside ACL tears or meniscal injury, whether addressed at the time of surgery or left to declare itself later through ongoing symptoms.

The injectable pathway carries no published upper ceiling on age or defect size, which distinguishes it from focal surgical reconstruction options. Patients for whom surgery is premature — because the joint is otherwise healthy, the defect pattern is too diffuse for a grafting approach, or because they wish to avoid theatre admission — sit within the realistic indication range. It is a bridge pathway, not a last resort.

What narrows the picture are the surrounding structures. Good candidates tend to have reasonably intact cartilage at the defect margins; when degeneration has spread more widely across the joint surface, management shifts toward joint-level strategies rather than focal scaffold support.

Active joint infection, local inflammation, and systemic inflammatory arthropathy — including rheumatoid conditions — are recognised contraindications. Candidacy in any individual case rests on clinical examination, imaging review, and a full history of prior knee procedures.

What the published outcomes show

The headline outcome across published knee cohorts is a mean IKDC improvement of approximately 30 points — consistently clearing the Minimal Clinically Important Difference of 16.7 points, the threshold at which patients themselves register meaningful change in daily activity and return to sport.

The most durable evidence comes from the Jerosch et al. prospective post-market follow-up study, which recorded a 32.4-point mean IKDC gain sustained — and marginally increased — at three-year follow-up, with patients reaching a mean functional score of 80. The three-year horizon matters: scaffold interventions can show early improvement that fades as material degrades without adequate cell recruitment. The Jerosch data suggest neither pattern is occurring.

MRI MOCART scores in European cohorts extend to 81.6–84.3 at twelve months. The upper portion of that band, beyond the one-year mean already established in the mechanism data, reflects genuine scaffold-to-native-cartilage integration rather than a discrete plug resting within the defect. Serial imaging also reinforces a practical expectation: a six-week scan does not represent the final tissue state, and clinical decisions drawn from early MRI alone would be premature.

Across more than 19,000 cases performed globally over a decade, the published complaint rate is approximately 0.06% — a safety signal consistent with an acellular, non-immunogenic material.

One honest caveat applies to the evidence base as a whole: the published studies are predominantly observational cohort data. A dedicated randomised controlled trial isolating post-ACL or post-meniscectomy patients as a defined subgroup has not been published. The consistency of IKDC gains across independent European cohorts is notable, but individual prognosis should be discussed with a specialist rather than read directly from population averages.

Getting an assessment and what to expect from the process

An assessment for injectable collagen scaffold treatment starts with a review of existing MRI, the history of the original knee injury — ACL tear, meniscal surgery, or both — and an account of any treatment already attempted. Together, these allow the clinician to judge defect characteristics, the condition of surrounding cartilage, and whether the injection pathway suits the individual clinical picture.

The treatment itself is placed under ultrasound guidance at an outpatient appointment; no theatre admission or surgical wound recovery is involved, as outlined in the mechanism section above. Afterwards, a period of activity modification is advisable — loading increases gradually over weeks rather than days as the collagen scaffold integrates and host-cell recruitment progresses. Tissue maturation continues for up to twelve months, so recovery expectations should be discussed and calibrated at the outset rather than revised reactively.

For patients who have reviewed the evidence and are weighing whether a formal assessment is the right next step, the important conclusion is this: published cohort data can establish that a 30-point IKDC improvement is achievable and that the safety record is reassuring — but individual suitability depends on the specific defect, the surrounding joint, and the full injury history, none of which population figures can substitute for. A clinical consultation is where that determination is made. London Cartilage Clinic on Harley Street offers specialist assessment for this pathway; patients outside London may be seen through the wider MSK Doctors group's Lincolnshire sites. To arrange an initial appointment, visit londoncartilage.com.